Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 704-712

  Aleem, Eiman ^a   Elshayeb, Ayman ^b   Elhabachi, Nihal ^b   Mansour, Amal Refaat ^b   Gowily, Ahmed ^b   Hela, Asmaa ^a  

^a Alexandria University Faculty Of Science   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Biomarker; Cirrhosis; Egypt; Hepatitis C virus; Hepatocellular carcinoma; Insulin like growth factor binding protein 3; Insulin like growth factor 1; Insulin like growth factor 2

Indexed keywords

ALPHA FETOPROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD LEVEL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84855656259     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.546     Document Type: Article

References (49)

1. Hsieh PM, Hung KC and Chen YS: Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. World J Gastroenterol 15: 4726-4728, 2009.
2. Anwar WA, Khaled HM, Amra HA, El-Nezami H and Loffredo CA: Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res 659: 176-184, 2008.
3. Sievert W, Altraif I, Razavi HA, et al: A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 31 Suppl 2: 61-80, 2011.
4. Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346, 2002.
5. Furstenberger G and Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol 3: 298-302, 2002.
6. Nehrbass D, Klimek F and Bannasch P: Overexpression of insulin receptor substrate-1 emerges early in hepatocarcinogenesis and elicits preneoplastic hepatic glycogenosis. Am J Pathol 152: 341-345, 1998.
7. Aleem E, Nehrbass D, Klimek F, Mayer D and Bannasch P: Upregulation of the insulin receptor and type I insulin-like growth factor receptor are early events in hepatocarcinogenesis. Toxicol Pathol 39: 524-543, 2011.
8. Rosen CJ and Pollak M: Circulating IGF-I: new perspectives for a new century. Trends Endocrinol Metab 10: 136-141, 1999.
9. Rosenfeld RG, Kofoed E, Little B, et al: Growth hormone insensitivity resulting from post-GH receptor defects. Growth Horm IGF Res 14 Suppl A: S35-S38, 2004.
10. Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995.
11. Mazziotti G, Sorvillo F, Morisco F, et al: Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 95: 2539-2545, 2002.
12. Su WW, Lee KT, Yeh YT, et al: Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal 24: 195-200, 2010.
13. Tovar V, Alsinet C, Villanueva A, et al: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 52: 550-559, 2010.
14. Sidlova K, Pechova M, Kotaska K and Prusa R: Insulin-like growth factor binding protein-3 in patients with liver cirrhosis. Physiol Res 51: 587-590, 2002.
15. Wu YL, Ye J, Zhang S, Zhong J and Xi RP: Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 10: 2740-2743, 2004.
16. Bruix J and Llovet JM: Hepatocellular carcinoma: is surveillance cost effective? Gut 48: 149-150, 2001.
17. Spangenberg HC, Thimme R and Blum HE: Serum markers of hepatocellular carcinoma. Semin Liver Dis 26: 385-390, 2006.
18. Srinivas PR, Kramer BS and Srivastava S: Trends in biomarker research for cancer detection. Lancet Oncol 2: 698-704, 2001.
19. Kato N, Yokosuka O, Omata M, Hosoda K and Ohto M: Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest 86: 1764-1767, 1990.
20. Aishima S, Basaki Y, Oda Y, et al: High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci 97: 1182-1190, 2006.
21. McShane LM, Altman DG and Sauerbrei W: Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 97: 1023-1025, 2005.
22. Shaarawy M, Fikry MA, Massoud BA and Lotfy S: Insulin-like growth factor binding protein-3: a novel biomarker for the assessment of the synthetic capacity of hepatocytes in liver cirrhosis. J Clin Endocrinol Metab 83: 3316-3319, 1998.
23. Mattera D, Capuano G, Colao A, et al: Increased IGF-I: IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin Endocrinol (Oxf) 59: 699-706, 2003.
24. Elsammak MY, Amin GM, Khalil GM, Ragab WS and Abaza MM: Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis. Clin Biochem 39: 623-629, 2006.
25. Okan A, Comlekci A, Akpinar H et al: Serum concentrations of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in patients with chronic hepatitis. Scand J Gastroenterol 35: 1212-1215, 2000.
26. Hanafusa T, Yumoto Y, Nouso K, et al: Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176: 149-158, 2002.
27. Luo SM, Tan WM, Deng WX, Zhuang SM and Luo JW: Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol 11: 4272-4276, 2005.
28. Huynh H, Chow PK, Ooi LL and Soo KC: A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 13: 115-122, 2002.
29. Park IY, Sohn BH, Yu E, et al: Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 132: 1476-1494, 2007.
30. Shon JK, Shon BH, Park IY, et al: Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription. Virus Res 139: 14-21, 2009.
31. Ricort JM, Lombet A, Lassarre C and Binoux M: Insulin-like growth factor binding protein-3 increases intracellular calcium concentrations in MCF-7 breast carcinoma cells. FEBS Lett 527: 293-297, 2002.
32. Ricort JM and Binoux M: Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase. Effects on the insulin-like growth factor signaling pathway. J Biol Chem 277: 19448-19454, 2002.
33. Ricort JM and Binoux M: Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells. Biochem Biophys Res Commun 314: 1044-1049, 2004.
34. Weng CJ, Hsieh YH, Tsai CM, et al: Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 17: 1808-1815, 2010.
35. El-Houseini ME, Mohammed MS, Elshemey WM, Hussein TD, Desouky OS and Elsayed AA: Enhanced detection of hepatocellular carcinoma. Cancer Control 12: 248-253, 2005.
36. Rehem RN and El-Shikh WM: Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepato-gastroenterology 58: 949-954, 2011.
37. Scharf JG, Ramadori G and Dombrowski F: Analysis of the IGF axis in preneoplastic hepatic foci and hepatocellular neoplasms developing after low-number pancreatic islet transplantation into the livers of streptozotocin diabetic rats. Lab Invest 80: 1399-1411, 2000.
38. Price JA, Kovach SJ, Johnson T, et al: Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology 36: 1089-1097, 2002.
39. Qian J, Yao D, Dong Z, et al: Characteristics of hepatic IGF-ii expression and monitored levels of circulating IGF-ii mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol 134: 799-806, 2010.
40. El Tayebi HM, Salah W, El Sayed IH et al: Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients. Biomarkers 16: 346-354, 2011.
41. Fan J, Upadhye S and Worster A: Understanding receiver operating characteristic (ROC) curves. CJEM 8: 19-20, 2006.
42. Scott CD, Martin JL and Baxter RC: Production of insulin-like growth factor I and its binding protein by adult rat hepatocytes in primary culture. Endocrinology 116: 1094-1101, 1985.
43. Chin E, Zhou J, Dai J, Baxter RC and Bondy CA: Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex. Endocrinology 134: 2498-2504, 1994.
44. Villafuerte BC, Koop BL, Pao CI, Gu L, Birdsong GG and Phillips LS: Coculture of primary rat hepatocytes and nonparenchymal cells permits expression of insulin-like growth factor binding protein-3 in vitro. Endocrinology 134: 2044-2050, 1994.
45. Scharf J, Ramadori G, Braulke T and Hartmann H: Synthesis of insulinlike growth factor binding proteins and of the acid-labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: regulation by insulin, insulinlike growth factor, and growth hormone. Hepatology 23: 818-827, 1996.
46. Scharf JG, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T and Hartmann H: Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis 19: 2121-2128, 1998.
47. Stuver SO, Kuper H, Tzonou A, et al: Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 87: 118-121, 2000.
48. Major JM, Stolzenberg-Solomon RZ, Pollak MN, Snyder K, Virtamo J and Albanes D: Insulin-like growth factors and liver cancer risk in male smokers. Br J Cancer 103: 1089-1092, 2010.
49. Bonefeld K and Moller S: Insulin-like growth factor-I and the liver. Liver Int 31: 911-919, 2011.